Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.

Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW.

ScientificWorldJournal. 2012;2012:170496. doi: 10.1100/2012/170496. Epub 2012 Aug 22.

2.

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.

Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K.

Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.

3.

The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.

Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA.

Oncologist. 2016 Jun;21(6):671-5. doi: 10.1634/theoncologist.2015-0470. Epub 2016 May 25.

4.

A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.

Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T.

JOP. 2013 Sep 10;14(5):498-501. doi: 10.6092/1590-8577/1589.

5.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA.

Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.

PMID:
23370660
6.

Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.

Mueller D, Krug S, Majumder M, Rinke A, Gress TM.

BMC Cancer. 2016 Aug 18;16:645. doi: 10.1186/s12885-016-2642-1.

7.

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH.

Cancer. 2013 Sep 1;119(17):3212-8. doi: 10.1002/cncr.28142. Epub 2013 Jun 3.

8.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS.

Clin Cancer Res. 2009 Jan 1;15(1):338-45. doi: 10.1158/1078-0432.CCR-08-1476.

9.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.

J Clin Oncol. 2006 Jan 20;24(3):401-6.

PMID:
16421420
10.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

Claringbold PG, Price RA, Turner JH.

Cancer Biother Radiopharm. 2012 Nov;27(9):561-9. doi: 10.1089/cbr.2012.1276. Epub 2012 Oct 18.

PMID:
23078020
11.

Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.

Sipos L, Vitanovics D, Afra D.

Ideggyogy Sz. 2004 Nov 20;57(11-12):394-9.

PMID:
15662767
12.

Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.

Sugimoto M, Takagi T, Hikichi T, Suzuki R, Watanabe K, Nakamura J, Kikuchi H, Konno N, Waragai Y, Asama H, Takasumi M, Watanabe H, Obara K, Ohira H.

World J Gastroenterol. 2015 Jul 14;21(26):8118-24. doi: 10.3748/wjg.v21.i26.8118.

13.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
14.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH.

J Clin Oncol. 2012 Aug 20;30(24):2963-8. doi: 10.1200/JCO.2011.40.3147. Epub 2012 Jul 9.

15.

Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.

Abbasi S, Kashashna A, Albaba H.

Pancreas. 2014 Nov;43(8):1303-5. doi: 10.1097/MPA.0000000000000174.

PMID:
25036906
16.

Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.

Daróczi B, Szántó E, Tóth J, Barzó P, Bognár L, Bakó G, Szántó J, Mózes P, Hideghéty K.

Ideggyogy Sz. 2013 Nov 30;66(11-12):391-8.

PMID:
24555238
17.

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.

Claringbold PG, Turner JH.

Neuroendocrinology. 2016;103(5):432-9. doi: 10.1159/000434723. Epub 2015 Jun 10.

PMID:
26065489
18.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.

Clin Cancer Res. 2007 May 15;13(10):2986-91.

19.

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).

J Transl Med. 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1.

20.

Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.

Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, Meeker A, Strosberg J.

Endocr Relat Cancer. 2016 Sep;23(9):759-67. doi: 10.1530/ERC-16-0147.

Supplemental Content

Support Center